Immunoblotting assay demonstrated that the levels of phosphorylated JNK and c-Jun in TMZ + FK866- or TMZ + CHS828-treated U251-MG glioblastoma cells were enhanced by ~2-fold compared with that in TMZ-treated cells (Figures 5(a)–5(c)). Here, MAPK8 is linked to glioblastoma.